Comparative Pharmacology
Head-to-head clinical analysis: EMETE CON versus MEZOFY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMETE CON versus MEZOFY.
EMETE-CON vs MEZOFY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antiemetic; dopaminergic antagonist at D2 receptors in the chemoreceptor trigger zone; also exhibits anticholinergic and antihistaminic properties.
MEZOFY is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
12.5 mg intravenously over 30 seconds as a single dose; may repeat once after 1 hour if necessary.
MEZOFY (mexiletine) 200 mg orally every 8 hours; may increase to 300 mg every 8 hours if needed.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours in adults with normal renal and hepatic function; may extend to 15-20 hours in elderly or patients with hepatic impairment.
Terminal half-life: 8-12 hours (mean 10 h); prolonged in renal impairment (up to 24 h in CrCl <30 mL/min)
Primarily hepatic metabolism (CYP2D6, CYP3A4) with <5% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 60-70% of metabolites, with renal elimination of metabolites constituting 25-35%.
Renal: 60% unchanged; biliary/fecal: 25% as metabolites; 15% other
Category C
Category C
Antiemetic
Antiemetic/Antivertigo